Logo image of JAN

JANONE INC (JAN) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:JAN - US47089W1045 - Common Stock

2.23 USD
+0.09 (+4.21%)
Last: 7/12/2024, 8:00:02 PM
Fundamental Rating

0

Taking everything into account, JAN scores 0 out of 10 in our fundamental rating. JAN was compared to 191 industry peers in the Pharmaceuticals industry. JAN may be in some trouble as it scores bad on both profitability and health. JAN does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

JAN had negative earnings in the past year.
JAN had a negative operating cash flow in the past year.
JAN had negative earnings in 4 of the past 5 years.
JAN had negative operating cash flow in 4 of the past 5 years.
JAN Yearly Net Income VS EBIT VS OCF VS FCFJAN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 5M -5M 10M -10M -15M

1.2 Ratios

Looking at the Return On Assets, with a value of -107.89%, JAN is doing worse than 83.08% of the companies in the same industry.
JAN's Return On Equity of -262.72% is on the low side compared to the rest of the industry. JAN is outperformed by 76.92% of its industry peers.
Industry RankSector Rank
ROA -107.89%
ROE -262.72%
ROIC N/A
ROA(3y)-43.38%
ROA(5y)-41.28%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
JAN Yearly ROA, ROE, ROICJAN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 0 100 -100 -200 -300

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for JAN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
JAN Yearly Profit, Operating, Gross MarginsJAN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 0 20 -20 -40

More info and screens

1

2. Health

2.1 Basic Checks

JAN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for JAN has been increased compared to 1 year ago.
Compared to 1 year ago, JAN has a worse debt to assets ratio.
JAN Yearly Shares OutstandingJAN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 1M 2M 3M 4M
JAN Yearly Total Debt VS Total AssetsJAN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M

2.2 Solvency

JAN has an Altman-Z score of -3.96. This is a bad value and indicates that JAN is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of JAN (-3.96) is worse than 60.00% of its industry peers.
JAN has a Debt/Equity ratio of 0.14. This is a healthy value indicating a solid balance between debt and equity.
JAN has a Debt to Equity ratio of 0.14. This is comparable to the rest of the industry: JAN outperforms 46.15% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.14
Debt/FCF N/A
Altman-Z -3.96
ROIC/WACCN/A
WACC9.51%
JAN Yearly LT Debt VS Equity VS FCFJAN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 10M 20M

2.3 Liquidity

JAN has a Current Ratio of 0.15. This is a bad value and indicates that JAN is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 0.15, JAN is doing worse than 98.46% of the companies in the same industry.
A Quick Ratio of 0.15 indicates that JAN may have some problems paying its short term obligations.
With a Quick ratio value of 0.15, JAN is not doing good in the industry: 97.95% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.15
Quick Ratio 0.15
JAN Yearly Current Assets VS Current LiabilitesJAN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M 25M

More info and screens

0

3. Growth

3.1 Past

JAN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -163.18%.
JAN shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
EPS 1Y (TTM)-163.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-110.79%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
JAN Yearly Revenue VS EstimatesJAN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for JAN. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
JAN Price Earnings VS Forward Price EarningsJAN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
JAN Per share dataJAN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for JAN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

JANONE INC

NASDAQ:JAN (7/12/2024, 8:00:02 PM)

2.23

+0.09 (+4.21%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-22 2024-05-22/amc
Earnings (Next)08-15 2024-08-15/amc
Inst Owners5.8%
Inst Owner Change0%
Ins Owners1.88%
Ins Owner Change0%
Market Cap26.02M
Revenue(TTM)N/A
Net Income(TTM)-20.04M
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.41
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-3.97
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.13
FCFYN/A
OCF(TTM)-0.13
OCFYN/A
SpS0
BVpS0.65
TBVpS-0.82
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -107.89%
ROE -262.72%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-43.38%
ROA(5y)-41.28%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.14
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.15
Quick Ratio 0.15
Altman-Z -3.96
F-Score1
WACC9.51%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-163.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-110.79%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-18.8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y65.58%
FCF growth 3YN/A
FCF growth 5Y-17.16%
OCF growth 1Y47.72%
OCF growth 3YN/A
OCF growth 5Y-18.82%

JANONE INC / JAN FAQ

Can you provide the ChartMill fundamental rating for JANONE INC?

ChartMill assigns a fundamental rating of 0 / 10 to JAN.


What is the valuation status for JAN stock?

ChartMill assigns a valuation rating of 0 / 10 to JANONE INC (JAN). This can be considered as Overvalued.


How profitable is JANONE INC (JAN) stock?

JANONE INC (JAN) has a profitability rating of 0 / 10.


How financially healthy is JANONE INC?

The financial health rating of JANONE INC (JAN) is 1 / 10.